Stock AXSM AXSOME THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Axsome Therapeutics, Inc.

Equities

AXSM

US05464T1043

Market Closed - Nasdaq
Other stock markets
 21:00:00 02/05/2024 BST 		5-day change 1st Jan Change
74.19 USD -0.93% Intraday chart for Axsome Therapeutics, Inc. +3.73% -6.78%
04-30 North American Morning Briefing : More Earnings -2- DJ
04-29 Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
GL
Axsome Therapeutics highlights innovative neuroscience portfolio at the american academy of neurology 2024 annual meeting
AQ
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
GL
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
AQ
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
GL
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
GL
Axsome Therapeutics : AXS-12 SYMPHONY Results - Slides
PU
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
GL
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
GL
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
GL
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
GL
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
AQ
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
GL
Enpro, Axsome Therapeutics fall; Walmart, Medtronic rise, Tuesday, 2/20/2024
AQ
Axsome: Q4 Earnings Snapshot
AQ
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GL
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
GL
Southern District Of New York Dismisses Proposed Securities Class Action Complaint Against Drug Manufacturer For Failure To Plead Loss Causation
AQ
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AXSM Stock
  4. News Axsome Therapeutics, Inc.
  5. Press Releases